Antiplatelet effect of 2-(diethylamino)-7-hydroxychromone

Pharmacol Res. 1991 Feb;23(2):139-48. doi: 10.1016/s1043-6618(05)80115-x.

Abstract

In this study the in vitro influence of 2-(diethylamino)-7-hydroxychromone (RC39II) on platelet aggregating responses, thromboxane A2 (TxA2) production, release reaction and intraplatelet cyclic AMP (cAMP) content has been investigated. The drug exerts a dose-dependent inhibitory effect on aggregating response to arachidonic acid, U46619, thrombin, collagen and calcium ionophore A23187. Inhibiting concentrations of RC39II also prevent platelet release reaction and TxA2 formation. RC39II potentiates platelet cAMP accumulation by Iloprost. Several studies, carried out on soluble cAMP phosphodiesterase (PDE) have shown that the drug inhibits phosphodiesterase in a dose-dependent manner. No effect was shown on adenylate cyclase activity from platelet membranes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Platelets / metabolism
  • Cyclic AMP / blood
  • Dose-Response Relationship, Drug
  • Humans
  • In Vitro Techniques
  • Phosphodiesterase Inhibitors
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors*
  • Thromboxane A2 / metabolism

Substances

  • Phosphodiesterase Inhibitors
  • Platelet Aggregation Inhibitors
  • Thromboxane A2
  • Cyclic AMP